Associated Genetic Biomarkers
PTPRC status serves as an inclusion eligibility criteria in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials that contain PTPRC status as an inclusion criterion, 2 are phase 2 (1 open) and 1 is phase 3 (1 open).
Trials with PTPRC status in the inclusion eligibility criteria most commonly target acute myeloid leukemia and non-small cell lung carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are PTPRC Expression and PTPRC Overexpression .
Allogeneic hematopoietic stem cell transplantation, capmatinib, fludarabine, gefitinib, and iodine i 131 apamistamab are the most frequent therapies in trials with PTPRC as an inclusion criteria .
Significance of PTPRC in Diseases
Acute Myeloid Leukemia +
PTPRC is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTPRC status and acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) .
Hepatocellular Carcinoma +
PTPRC is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTPRC status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Non-Small Cell Lung Carcinoma +
PTPRC is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPRC status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.